Luminal B 型乳腺癌不同亚型的临床病理特征及预后生存分析.

To analyze the clinicopathological features and prognosis difference of Luminal B type breast cancer patients with different subtypes. The clinicopathological and follow-up data of 359 cases of primary Luminal B type breast cancer patients who were admitted to Xuhui And Lingang Hospitals of Shanghai Sixth People's Hospital from January 2006 to January 2016 were retrospectively analyzed. According to Luminal B type breast cancer molecular subtypes, the patients were divided into the human epidermal growth receptor 2 (Her-2) negative group (266 cases) and the Her-2 positive group (93 cases). The clinicopathological features difference of the two groups were compared. Kaplan-meier survival curve was drawn to analyze the difference of 5-year progression-free survival rate and overall survival rate between the two groups, and Cox proportional regression was used to analyze the influencing factors of the prognosis of Luminal B type breast cancer patients. TNM stage III～IV stage, tumor histological grade III grade, PR negative, Ki-67 high expression and lymph node metastasis proportion in Her-2 positive group were higher than those in Her-2 negative group (P＜ 0.05). The 5-year DFS and OS survival rates in Her-2 positive group were 12.90% and 40.86%, respectively, which were lower than 24.06% and 59.77% in Her-2 negative group (Log-Rank χ2 =14.500, 12.860, P=0.000, 0.000). TNM stage III～IV stage, lymph node metastasis, Her-2 positive and PR negativewere the risk factors for poor prognosis in Luminal B type breast cancer patients ( P ＜ 0.05). There are differences in TNM stage, tumor histological grade, lymph node metastasis, Ki-67 and PR expression in different molecular subtypes of Luminal B type breast cancer patients. Meanwhile, TNM stage, lymph node metastasis, Her-2 positive and PR negative are risk factors for poor prognosis in Luminal B type breast cancer patients. [ABSTRACT FROM AUTHOR]